Loading...
SpringWorks Therapeutics, Inc.
SWTX•NASDAQ
Healthcare
Biotechnology
$46.99
$0.00(0.00%)
SpringWorks Therapeutics, Inc. (SWTX) Financial Performance & Income Statement Overview
Review SpringWorks Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
3417.33%
↑ 3417.33%
Operating Income Growth
18.92%
↑ 18.92%
Net Income Growth
20.60%
↑ 20.60%
Operating Cash Flow Growth
21.18%
↑ 21.18%
Operating Margin
-120.52%
↓ 120.52%
Gross Margin
93.23%
↑ 93.23%
Net Profit Margin
-115.60%
↓ 115.60%
ROE
-51.10%
↓ 51.10%
ROIC
-62.57%
↓ 62.57%
SpringWorks Therapeutics, Inc. (SWTX) Income Statement & Financial Overview
Review SpringWorks Therapeutics, Inc.'s (SWTX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $61.55M | $49.30M | $59.73M | $21.006M |
| Cost of Revenue | $5.55M | $3.34M | $2.45M | $1.93M |
| Gross Profit | $55.99M | $45.96M | $57.28M | $19.07M |
| Gross Profit Ratio | $0.91 | $0.93 | $0.96 | $0.91 |
| R&D Expenses | $60.24M | $42.30M | $44.36M | $53.62M |
| SG&A Expenses | $77.10M | $61.60M | $57.84M | $59.38M |
| Operating Expenses | $137.34M | $103.90M | $102.20M | $113.006M |
| Total Costs & Expenses | $142.89M | $107.24M | $104.65M | $114.94M |
| Interest Income | $5.43M | $6.22M | $6.78M | $7.57M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.02M | $878000.00 | $844000.00 | $729000.00 |
| EBITDA | -$80.33M | -$57.06M | -$44.08M | -$93.20M |
| EBITDA Ratio | -$1.31 | -$1.16 | -$0.74 | -$4.44 |
| Operating Income | -$81.34M | -$57.94M | -$44.92M | -$93.93M |
| Operating Income Ratio | -$1.32 | -$1.18 | -$0.75 | -$4.47 |
| Other Income/Expenses (Net) | $4.04M | $4.41M | $5.002M | $6.55M |
| Income Before Tax | -$77.30M | -$53.53M | -$39.92M | -$87.39M |
| Income Before Tax Ratio | -$1.26 | -$1.09 | -$0.67 | -$4.16 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $685724.00 |
| Net Income | -$77.30M | -$53.53M | -$39.92M | -$87.39M |
| Net Income Ratio | -$1.26 | -$1.09 | -$0.67 | -$4.16 |
| EPS | -$1.04 | -$0.72 | -$0.54 | -$1.18 |
| Diluted EPS | -$1.04 | -$0.72 | -$0.54 | -$1.18 |
| Weighted Avg Shares Outstanding | $74.13M | $74.26M | $74.12M | $73.77M |
| Weighted Avg Shares Outstanding (Diluted) | $74.13M | $74.26M | $74.12M | $73.77M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan